Abstract
The recent clinical success of chemically induced pluripotent stem cell (CiPSC)-derived islet transplantation for type 1 diabetes represents a landmark achievement in regenerative medicine. This article delves into the groundbreaking work presented by Dr. Hongkui Deng and Dr. Candice S.Y. Liew at International Society for Stem Cell Research (ISSCR) 2025, focusing on their innovative chemical reprogramming technology and its clinical application. The discussion highlights the scientific rationale behind chemical reprogramming, the development of functional islets, the novel transplantation strategy, and the remarkable clinical outcomes observed in their first patient. The implications for future stem cell therapies and the challenges of scalability are also explored.